Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Festival Offer
This Diwali, Light up your portfolio with MoneyWorks4me Superstars starting @ ₹ 7,999 ₹ 5,999 (Offer valid till 3rd Nov 21)
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Tonira Pharma Ltd Stock Analysis

Small Cap
Evaluated by 40 users | BSE: 530155 | NSE: |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'02Mar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11TTM
Return on Capital Employed 13.7%17.47%2.53%6.73%7.49%7.47%-4.73%10.77%6.22%-1.77%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 19.42426.222.529.436.832.641.336.930.233
Y-o-Y Gr. Rt.-23.3%9.1%-13.8%30.3%25.2%-11.5%26.8%-10.7%-18.1%-
Adjusted EPS (Rs.) 2.383.440.121.832.292.15-4.312.480.82-3.82-4.22
Y-o-Y Gr. Rt.-44.5%-96.5%1425%25.1%-6.1%-300.5%NA-66.9%-565.9%-
Book Value per Share (Rs.) 15.4316.4917.5420.9723.0424.6917.4616.418.0515.4312.54
Adjusted Net Profit 1.92.70.11.51.81.7-3.420.7-3-3
Net Op. Cash Flow (Rs. Cr.) 2.84.52.73.7-0.65.1-7.13.87.5-0.9-
Debt to Cash Flow from Ops 2.090.82.524.16-37.723.88-4.057.084.2-39.44-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Tonira Pharma Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 5%0.6%-2.5%-18.1%
Adjusted EPS -205.4%-210.8%NA-565.9%
Book Value per Share 0-7.7-4-14.5
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'02Mar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11TTM
Return on Equity (%) 16.220.970.689.4210.338.86-19.9714.384.76-22.82-30.18
Operating Profit Margin (%) 6.677.285.3317.4421.7619.3-3.0623.9317.168.110.73
Net Profit Margin (%) 9.7111.410.366.446.184.64-10.534.781.78-10.06-10.01
Debt to Equity 0.470.270.490.921.1712.082.072.183-
Working Capital Days 219182157186185189240211248314-
Cash Conversion Cycle 12280649397100128100131187-
Loading price chart...
Entity Percentage Holding
Promoters 37.27%
Non-Institutions 62.73%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Data is not available for this company.

Tonira Pharma incorporated, in 1992, is engaged in the business of manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and intermediates.

The company's manufacturing locations at Nandesari and Ankleshwar are inspected and approved by PMDA Japan. With the USFDA approval of the Nandesari plant and PMDA Japan approvals of both the plants, the company will now have access to regulated markets for its APIs.

Tonira operates a state-of-the-art R&D Center at Nandesari,

Tonira Pharma incorporated, in 1992, is engaged in the business of manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and intermediates.

The company's manufacturing locations at Nandesari and Ankleshwar are inspected and approved by PMDA Japan. With the USFDA approval of the Nandesari plant and PMDA Japan approvals of both the plants, the company will now have access to regulated markets for its APIs.

Tonira operates a state-of-the-art R&D Center at Nandesari, Vadodara District in Gujarat. The centre is continuously developing newer value-added APIs through innovative and cost-effective processes.

Tonira undertakes contract synthesis both on exclusive and non-exclusive basis.  The company has the capability to provide contract research and manufacturing services to its customers.

Products

APIs- Under this, the company manufactures Atenolo, Aceclofenac, Benzbromarone, Benzarone, Desloratadine, Ebastine, Famotidine, Glimepiride, Loratadine, Meloxicam, Mosapride Citrate, Nifedipine, Ofloxacin, Quetiapine Fumarate, Sodium Alendronate, Tramadol HCI, Tamsulosin HCI and Zolpidem Tartrate.

Recognitions/Achievements

  • Tonira Pharma has received WHO-GMP approval for its manufacturing facility.
  • The company is recipient of export award for two successive years from DGFT.
  • Its R&D centre is recognized by Department of Science & Technology, Government of India.
  • The company has been recognised as an Export House by Government of India.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback